Common use of Other Licensed Molecule Clause in Contracts

Other Licensed Molecule. From time to time during the Term of this Agreement, Company will present to the JSC with reasonable information regarding any [ * ] (each, an “Other Licensed Molecule”). At the request of Licensee with [ * ] to be agreed in good faith by the Parties, Company will transfer to Licensee Materials and further Information reasonably required by Licensee in order to evaluate, test, and assess the development and commercial potential of each such Other Licensed Molecule. Licensee may in its sole discretion at any time during the Term elect to advance such Other Licensed Molecule by written notice to Company, it being understood that Licensee will not [ * ] an [ * ] on an Other Licensed Molecule without first making such election. Upon such written election, Licensee shall pay to Company [ * ] within [ * ] after such election and such Other Licensed Molecule will be subject to the royalty provisions [ * ]. Except for the foregoing, and notwithstanding anything to the contrary in this Agreement, Licensee will have no other royalty, upfront, milestone or other payment obligations to Licensee or its Affiliates relating to any Other Licensed Molecule or the Development, Manufacturing or Commercialization thereof. For clarity, Licensee shall not have any obligation to pay any upfront or milestone payment contemplated in Section 8.1, Section 8.4 or Section 8.5 with respect to any Other Licensed Molecule.

Other Licensed Molecule. From time to time during the Term of this Agreement, Company will present to the JSC with reasonable information regarding any [ * [*] (each, an “Other Licensed Molecule”). At the request of Licensee with [ * [*] to be agreed in good faith by the Parties, Company will transfer to Licensee Materials and further Information reasonably required by Licensee in order to evaluate, test, and assess the development and commercial potential of each such Other Licensed Molecule. Licensee may in its sole discretion at any time during the Term elect to advance such Other Licensed Molecule by written notice to Company, it being understood that Licensee will not [ * [*] an [ * [*] on an Other Licensed Molecule without first making such election. Upon such written election, Licensee shall pay to Company [ * [*] within [ * [*] after such election and such Other Licensed Molecule will be subject to the royalty provisions [ * [*]. Except for the foregoing, and notwithstanding anything to the contrary in this Agreement, Licensee will have no other royalty, upfront, milestone or other payment obligations to Licensee or its Affiliates relating to any Other Licensed Molecule or the Development, Manufacturing or Commercialization thereof. For clarity, Licensee shall not have any obligation to pay any upfront or milestone payment contemplated in Section 8.1, Section 8.4 or Section 8.5 with respect to any Other Licensed Molecule.